Pro-Neurotensin As a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2022 Jun 30

PMID 35769889

Authors

Amal A Mohamed

Dina M Abo-Elmatty

Omnia Ezzat

Noha M Mesbah

Nada S Ali

Aliaa Sayed Abd El Fatah

Eman Alsayed

Mahmoud Hamada

Alshymaa A Hassnine

Sherief Abd-Elsalam

Ahmed Abdelghani

Mohamed Badr Hassan

Shaimaa A Fattah

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Currently, liver biopsy is the gold standard method for diagnosis of non-alcoholic fatty liver severity. It is critical to develop non-invasive diagnostic method to diagnose nonalcoholic fatty liver rather than invasive techniques. Our case-control study was to address the value of circulating miRNA-122 and serum pro-neurotensin as a potential non-invasive biomarker for the diagnosis of non-alcoholic fatty acid diseases.

Methods: Clinical assessment, laboratory investigations, and anthropometric measurements were reported for 157 patients with proven NAFLD. Apparently, healthy participants (n=100) were enrolled as a control group. Serum samples were tested for micro-RNAs-122 and pro-neurotensin.

Results: Compared with the control subjects, both mi-RNA-122 and serum proneurotensin levels were increased in NAFLD (p<0.001) and at a cut-off ≥6.83, mi-RNA-122 had 51.0% sensitivity, 70.0% specificity to differentiate NAFLD from healthy controls, while serum proneurotensin had 80.0% sensitivity and 80.0% specificity at a cutoff ≥108.

Conclusion: The circulating pro-neurotensin might be used as a novel biomarker for diagnosis of patients with NAFLD, wherefore the integration of a circulating mi-RNA-122 and serum pro-neurotensin could be beneficial to diagnose NAFLD cases. Large-scale studies are needed to investigate the possible role of mi-RNA-122 and pro-neurotensin in the development, progression, and prognosis of NAFLD and NASH.

Citing Articles

miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease-A New Diagnostic Path?.

Michalak A, Guz M, Kozicka J, Cybulski M, Jeleniewicz W, Telejko I Biomedicines. 2025; 13(1).

PMID: 39857813 PMC: 11762403. DOI: 10.3390/biomedicines13010230.

Evaluating the Feasibility of Pro-Neurotensin and 25-Hydroxyvitamin D3 as Possible Indicators for Type 2 Diabetes Mellitus and Its Complications.

Mohammed A, Abo El-Matty D, Abd ElSalam E, Hussein M, Hafez W, Ibrahim S Healthcare (Basel). 2023; 11(8).

PMID: 37107924 PMC: 10138095. DOI: 10.3390/healthcare11081088.

References

Ferris C, Hammer R, Leeman S . Elevation of plasma neurotensin during lipid perfusion of rat small intestine. Peptides. 1981; 2 Suppl 2:263-6. DOI: 10.1016/0196-9781(81)90042-5. View

Goedert M, Emson P . The regional distribution of neurotensin-like immunoreactivity in central and peripheral tissues of the cat. Brain Res. 1983; 272(2):291-7. DOI: 10.1016/0006-8993(83)90576-0. View

Mohamed A, Ghany M, Hakeem G, Mostafa A, Khattab R, Abdalla A . Erratum to: Assessment of Vitamin D status in a group of Egyptian children with non alcoholic fatty liver disease (multicenter study). Nutr Metab (Lond). 2016; 13:83. PMC: 5116213. DOI: 10.1186/s12986-016-0140-8. View

Leeman S, Carraway R . Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann N Y Acad Sci. 1982; 400:1-16. DOI: 10.1111/j.1749-6632.1982.tb31557.x. View

Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y . An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009; 30(12):2064-9. DOI: 10.1093/carcin/bgp283. View

Ardekani A, Naeini M . The Role of MicroRNAs in Human Diseases. Avicenna J Med Biotechnol. 2013; 2(4):161-79. PMC: 3558168. View

Mohamed A, Ahmed H, ElSadek S, Mohamed R, El-Amir R, Salah W . A study of leptin and its gene 2548 G/A Rs7799039 single-nucleotide polymorphisms in Egyptian children: A single-center experience. Clin Res Hepatol Gastroenterol. 2021; 45(5):101724. DOI: 10.1016/j.clinre.2021.101724. View

Pirola C, Fernandez Gianotti T, Castano G, Mallardi P, San Martino J, Gonzalez Lopez Ledesma M . Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2014; 64(5):800-12. PMC: 4277726. DOI: 10.1136/gutjnl-2014-306996. View

Tryndyak V, Latendresse J, Montgomery B, Ross S, Beland F, Rusyn I . Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol. 2012; 262(1):52-9. PMC: 4281090. DOI: 10.1016/j.taap.2012.04.018. View

10.

Wasfy E, Elkassas G, Elnawasany S, Elkasrawy K, Abd-Elsalam S, Soliman S . Predicting Esophageal Varices in Cirrhotic Hepatitis C Virus Patients Using Noninvasive Measurement of Insulin Resistance Variables. Endocr Metab Immune Disord Drug Targets. 2018; 18(6):573-580. DOI: 10.2174/1871530318666180803120428. View

11.

Chen C, Tan R, Wong L, Fekete R, Halsey J . Quantitation of microRNAs by real-time RT-qPCR. Methods Mol Biol. 2010; 687:113-34. DOI: 10.1007/978-1-60761-944-4_8. View

12.

Lee R, Ambros V . An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 294(5543):862-4. DOI: 10.1126/science.1065329. View

13.

Salvoza N, Klinzing D, Gopez-Cervantes J, Baclig M . Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2016; 11(4):e0153497. PMC: 4831793. DOI: 10.1371/journal.pone.0153497. View

14.

Cermelli S, Ruggieri A, Marrero J, Ioannou G, Beretta L . Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011; 6(8):e23937. PMC: 3160337. DOI: 10.1371/journal.pone.0023937. View

15.

Soliman H, Ziada D, Salama M, Hamisa M, Badawi R, Hawash N . Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study. Endocr Metab Immune Disord Drug Targets. 2019; 20(1):104-111. DOI: 10.2174/1871530319666190826150344. View

16.

El-Gebaly F, Abou-Saif S, Elkadeem M, Helmy A, Abd-Elsalam S, Yousef M . Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. Curr Cancer Drug Targets. 2019; 19(11):896-905. DOI: 10.2174/1568009619666190718141647. View

17.

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

18.

Becker P, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H . Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One. 2015; 10(11):e0142661. PMC: 4643880. DOI: 10.1371/journal.pone.0142661. View

19.

Weiland M, Gao X, Zhou L, Mi Q . Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012; 9(6):850-9. DOI: 10.4161/rna.20378. View

20.

Auguet T, Aragones G, Berlanga A, Guiu-Jurado E, Marti A, Martinez S . miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016; 17(10). PMC: 5085653. DOI: 10.3390/ijms17101620. View